CA-ANDERSEN-GLOBAL
Andersen fortsætter med at styrke sin problemfri service til kunder rundt om i verden, og deres brand følger efter, når Andersen Globals medlemsfirmaer i Mellemøsten nu opererer under brandet ”Andersen”. Meddelelsen kommer i forbindelse med optagelsen af brandet ”Andersen” blandt europæiske og latinamerikanske medlemsfirmaer tidligere i år.
Andersen Global-medlemsfirmaer, der tidligere opererede under brands ”Andersen Tax” og ”Andersen Tax & Legal” i Egypten, Jordan og Kuwait går nu over til det fælles brand ”Andersen”. Derudover byder Andersen velkommen til medlemsfirmaet Alrikaz i kongeriet Saudi-Arabien (KSA), som også tager Andersen-brandet til sig. Optagelsen af det fælles brand i regionen reflekterer på bedste vis det fulde omfang af den globale service, som Andersen-medlemsfirmaer tilbyder deres kunder, inklusive juridisk service i 16 lande, hvoraf to er i Mellemøsten.
Udover sine medlemsfirmaer i Egypten, Jordan, Kuwait og KSA er Andersen Global også tilstede i Mellemøsten i Bahrain, Libanon, Oman, Palæstina, Qatar og De Forenede Arabiske Emirater via samarbejdsfirmaer, med planer for fremtidig ekspansion.
”Vores optagelse af et fælles globalt brand viser hvor langt vi er kommet som organisation, og hvor vi er på vej hen”, sagde Mark Vorsatz, Andersen Global Chairman og Andersen CEO. ”Vi er engageret i at skabe en benchmarkingorganisation, som sætter den globale standard for den bedste uafhængige og synergistiske service i sin klasse. Vores fælles brand kendetegner vores problemfri service og delte centrale værdier rundt om i verden.”
Grundlaget for Andersens globale platform går helt tilbage til 2002, hvor 23 tidligere Arthur Andersen-partnere oprettede et firma, der kun beskæftigede sig med skat, WTAS LLC, som efterfulgtes af Andersen Global (tidligere WTAS Global) i 2014. Det samme år tog det grundlæggende amerikanske medlemsfirma brandet ”Andersen Tax” til sig, efterfulgt af medlemsfirmaer i Latinamerika, Europa og Afrika. Andersen Tax og Andersen Tax & Legal debuterede i Mellemøsten i 2017, og regionen er siden blevet udvidet til i dag at omfatte mere end 20 lokationer, 500 medarbejdere indenfor skat og jura, og næsten 100 partnere.
”Mellemøsten er et marked under udvikling, og skattebranchen er i fremgang, med særlig fokus på diversificering af økonomier,” sagde Fouad Al Hourani, Co-Regional Managing Director i Mellemøsten. ”Ved at tilbyde omfattende, problemfrie servicer, inklusive skat og jura, har vi lagt et solidt grundlag, og skabt en konkurrencedygtig platform for vores organisation i regionen.”
Lena Hamdi, Co-Regional Managing Director i Mellemøsten, tilføjer: ”Vores medlemsfirmaers servicetilbud gør os i stand til at opfylde vores kunders behov uanset grænser. Et fælles brand er en milepæl for vores organisation, og vi ser frem til dette næste trin af regionens udvikling.”
I løbet af det næste år fortsætter medlemsfirmaer i Afrika, Canada og Israel med at optage det fælles Andersen-brand, mens Andersen Global fortsætter med at udvide på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Siden oprettelsen i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 6.000 eksperter globalt og er repræsenteret på over 214 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20201111005886/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
